BiotechTube

mRNA-3745

Phase 2Active
1 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease

Conditions

Glycogen Storage Disease

Trial Timeline

Jun 1, 2022 → Nov 30, 2026

NCT ID
NCT05095727

About mRNA-3745

mRNA-3745 is a phase 2 stage product being developed by Moderna for Glycogen Storage Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05095727. Target conditions include Glycogen Storage Disease.

What happened to similar drugs?

3 of 7 similar drugs in Glycogen Storage Disease were approved

Approved (3) Terminated (0) Active (4)
🔄avalglucosidase alfaSanofiPhase 3
✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
✅Avalglucosidase alfa (GZ402666)SanofiApproved
🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
✅Avalglucosidase alfaSanofiApproved
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05095727Phase 2Active

Competing Products

20 competing products in Glycogen Storage Disease

See all competitors
ProductCompanyStageHype Score
alglucosidase alfaSanofiPre-clinical
26
avalglucosidase alfaSanofiPhase 3
44
MyozymeSanofiPhase 2/3
38
MyozymeSanofiPre-clinical
26
Avalglucosidase AlfaSanofiPhase 2
35
MyozymeSanofiPhase 2/3
38
ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved
43
Avalglucosidase alfa (GZ402666)SanofiApproved
47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
39
Alglucosidase alfaSanofiPhase 2
35
Avalglucosidase alfaSanofiApproved
50
MyozymeSanofiPhase 1/2
32
Alglucosidase alfa GZ419829SanofiPre-clinical
30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
26
alglucosidase alfaSanofiPre-clinical
26
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
BEAM-301: Single dose of BEAM-301 administered by IVBeam TherapeuticsPhase 1/2
33
Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3
34
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
18